Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio January 9, 2026 At a Case Management Conference in the multidistrict litigation (MDL) against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first trial, which will take place in December 2026, as more than 2,100 women pursue litigation alleging Pfizer failed to adequately warn patients despite long-standing knowledge of the risk. The hearing […] Read More
FDA: Depo-Provera Labels Must Warn of Meningioma Risk December 22, 2025 Labels for Pfizer’s Depo-Provera contraceptive injection must now warn of the risk of meningioma, a type of brain tumor. The U.S. Food and Drug Administration (FDA) required the label change last week. The warning applies to two injectable forms of the drug, Depo-Provera CI and Depo-Subq Provera 104, which consist of progestin, a synthetic form […] Read More
New Study Links Depo-Provera to Higher Risk of Brain Tumor October 6, 2025 A new study published in JAMA Neurology in September 2025 found that women in the United States who use the birth control shot Depo-Provera (depot medroxyprogesterone acetate, or DMPA) may face a higher risk of developing meningioma, a type of brain tumor that forms in the membranes surrounding the brain and spinal cord. Key Findings […] Read More
Levin Law
Levin Law